ACAD
Price
$21.85
Change
+$0.16 (+0.74%)
Updated
May 21 closing price
Capitalization
3.63B
69 days until earnings call
COGT
Price
$4.98
Change
-$0.33 (-6.21%)
Updated
May 21 closing price
Capitalization
604.58M
82 days until earnings call
Interact to see
Advertisement

ACAD vs COGT

Header iconACAD vs COGT Comparison
Open Charts ACAD vs COGTBanner chart's image
ACADIA Pharmaceuticals
Price$21.85
Change+$0.16 (+0.74%)
Volume$2.62M
Capitalization3.63B
Cogent Biosciences
Price$4.98
Change-$0.33 (-6.21%)
Volume$2.06M
Capitalization604.58M
ACAD vs COGT Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. COGT commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and COGT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (ACAD: $21.85 vs. COGT: $4.98)
Brand notoriety: ACAD and COGT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 120% vs. COGT: 152%
Market capitalization -- ACAD: $3.63B vs. COGT: $604.58M
ACAD [@Biotechnology] is valued at $3.63B. COGT’s [@Biotechnology] market capitalization is $604.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileCOGT’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • COGT’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than COGT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 6 TA indicator(s) are bullish while COGT’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 6 bullish, 5 bearish.
  • COGT’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, COGT is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +27.33% price change this week, while COGT (@Biotechnology) price change was +2.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.07%. For the same industry, the average monthly price growth was +10.40%, and the average quarterly price growth was -0.77%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

COGT is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.63B) has a higher market cap than COGT($605M). ACAD YTD gains are higher at: 19.074 vs. COGT (-36.154). ACAD has higher annual earnings (EBITDA): 102M vs. COGT (-284.04M). ACAD has more cash in the bank: 682M vs. COGT (246M). COGT has less debt than ACAD: COGT (17.1M) vs ACAD (56M). ACAD has higher revenues than COGT: ACAD (996M) vs COGT (0).
ACADCOGTACAD / COGT
Capitalization3.63B605M600%
EBITDA102M-284.04M-36%
Gain YTD19.074-36.154-53%
P/E Ratio15.95N/A-
Revenue996M0-
Total Cash682M246M277%
Total Debt56M17.1M327%
FUNDAMENTALS RATINGS
ACAD vs COGT: Fundamental Ratings
ACAD
COGT
OUTLOOK RATING
1..100
2419
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
10074
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3763
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (64) in the Biotechnology industry is in the same range as COGT (81) in the Miscellaneous industry. This means that ACAD’s stock grew similarly to COGT’s over the last 12 months.

COGT's Profit vs Risk Rating (74) in the Miscellaneous industry is in the same range as ACAD (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to ACAD’s over the last 12 months.

COGT's SMR Rating (100) in the Miscellaneous industry is in the same range as ACAD (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's Price Growth Rating (37) in the Biotechnology industry is in the same range as COGT (63) in the Miscellaneous industry. This means that ACAD’s stock grew similarly to COGT’s over the last 12 months.

ACAD's P/E Growth Rating (99) in the Biotechnology industry is in the same range as COGT (100) in the Miscellaneous industry. This means that ACAD’s stock grew similarly to COGT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADCOGT
RSI
ODDS (%)
Bearish Trend 1 day ago
73%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
64%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 6 days ago
73%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PDIAX21.59N/A
N/A
Virtus KAR Equity Income A
MSEGX54.56N/A
N/A
Morgan Stanley Inst Growth A
RAPRX10.83N/A
N/A
Cohen & Steers Real Assets R
GCSUX26.56N/A
N/A
Goldman Sachs Small Cap Eq Insghts R6
ABALX34.88-0.40
-1.13%
American Funds American Balanced A

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
-6.21%
SPHDF - COGT
63%
Loosely correlated
N/A
IDYA - COGT
53%
Loosely correlated
-2.45%
XNCR - COGT
52%
Loosely correlated
-7.62%
ETNB - COGT
52%
Loosely correlated
+6.42%
RCKT - COGT
51%
Loosely correlated
-3.80%
More